Comparison of the Structure and Function of Phospholamban and the Arginine-14 Deficient Mutant Associated with Dilated Cardiomyopathy
Open Access
- 16 September 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9) , e106746
Abstract
Phospholamban (PLB) is a pentameric protein that plays an important role in regulating cardiac contractility via a reversible inhibitory association with the sarcoplasmic reticulum Ca2+ATPase (SERCA), the enzyme responsible for maintaining correct calcium homeostasis. Here we study the functional and biophysical characteristics of a PLB mutant associated with human dilated cardiomyopathy (DCM), with a deletion of arginine at position 14 (PLBR14Δ). In agreement with recent findings, we find that PLBR14Δ has a reduced inhibitory effect on SERCA compared to wild type PLB (PLBWT) when reconstituted into lipid membranes. The mutation also leads to a large reduction in the protein kinase A-catalysed phosphorylation of Ser-16 in the cytoplasmic domain of PLBR14Δ. Measurements on SERCA co-reconstituted with an equimolar mixture of PLBWT and PLBR14Δ (representing the lethal heterozygous state associated with DCM) indicates that the loss-of-function mutation has a dominant effect on PLBWT functionality and phosphorylation capacity, suggesting that mixed PLBWT/PLBR14Δ pentamers are formed that have characteristics typical of the mutant protein. Structural and biophysical analysis of PLBR14Δ indicates that the mutation perturbs slightly the helical structure of the PLB cytoplasmic domain and reduces its affinity for the phospholipid bilayer surface, thereby altering the orientation of the cytoplasmic domain relative to the wild-type protein. These results indicate that the structure and function consequences of the R14 deletion have profound effects on the regulation of SERCA which may contribute to the aetiology of DCM.Keywords
This publication has 51 references indexed in Scilit:
- The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPaseJournal of Molecular and Cellular Cardiology, 2012
- Phospholamban mutants compete with wild type for SERCA binding in living cellsBiochemical and Biophysical Research Communications, 2012
- cAMP-Dependent Protein Kinase A Selects the Excited State of the Membrane Substrate PhospholambanJournal of Molecular Biology, 2011
- Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR methodProceedings of the National Academy of Sciences of the United States of America, 2011
- Lipid-Mediated Folding/Unfolding of Phospholamban as a Regulatory Mechanism for the Sarcoplasmic Reticulum Ca2+-ATPaseJournal of Molecular Biology, 2011
- Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failureBiochemical and Biophysical Research Communications, 2011
- Lethal Arg9Cys phospholamban mutation hinders Ca 2+ -ATPase regulation and phosphorylation by protein kinase AProceedings of the National Academy of Sciences, 2011
- Superinhibitory Phospholamban Mutants Compete with Ca2+ for Binding to SERCA2a by Stabilizing a Unique Nucleotide-dependent Conformational StateJournal of Biological Chemistry, 2010
- Effect of Membrane Thickness on Conformational Sampling of Phospholamban from Computer SimulationsBiophysical Journal, 2010
- Structure and topology of monomeric phospholamban in lipid membranes determined by a hybrid solution and solid-state NMR approachProceedings of the National Academy of Sciences of the United States of America, 2009